Our Patented Immunotechnology
ADMA has developed a patented process to manufacture a unique polyclonal immune globulin
Screen and identify high-titer donors
Hyperimmune donors with high-titer antibodies to select pathogens are identified.
A proprietary microneutralization assay quantitatively measures titer levels of neutralizing respiratory syncytial virus (RSV) antibodies in hyperimmune plasma donor samples.
Tailored plasma pools are derived from a unique blend of normal source plasma and plasma obtained from the selected donors.
The type of plasma used in immune globulin manufacturing can determine the level of antibody to specific pathogens1,2
*The following patents are applied to ASCENIV™ (immune globulin intravenous, human–slra): 9,107,906 composition, 9,714,283, use 9,815,886 methods expiration 2035.References:
- Barahona Afonso AF, João CM. The production processes and biological effects of intravenous immunoglobulin. Biomolecules. 2016;6(1):15. Published 2016 Mar 9.
- Orange JS, Du W, Falsey AR. Therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses. Front Immunol. 2015;6,431.